[1]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5), E359-E386.
[2]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
[3]
Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60(5), 277-300.
[4]
Van Cutsem, E.; Nordlinger, B.; Adam, R.; Köhne, C-H.; Pozzo, C.; Poston, G.; Ychou, M.; Rougier, P. European Colorectal Metastases Treatment, G. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur. J. Cancer, 2006, 42(14), 2212-2221.
[5]
Grothey, A. Is there a third-line therapy for metastatic colorectal cancer? Semin. Oncol., 2006, 33(6)(Suppl. 11), S36-S38.
[6]
Wu, D-M.; Wang, Y-J.; Fan, S-H.; Zhuang, J.; Zhang, Z-F.; Shan, Q.; Han, X-R.; Wen, X.; Li, M-Q.; Hu, B.; Sun, C-H.; Bao, Y-X.; Xiao, H-J.; Yang, L.; Lu, J.; Zheng, Y-L. Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer. Oncotarget, 2017, 8, 100668-100677.
[7]
Kirstein, M.M.; Lange, A.; Prenzler, A.; Manns, M.P.; Kubicka, S.; Vogel, A. Targeted therapies in metastatic colorectal cancer: A systematic review and assessment of currently available data. Oncologist, 2014, 19(11), 1156-1168.
[8]
Marques, A.M.; Turner, A.; de Mello, R.A. Personalizing medicine for metastatic colorectal cancer: current developments. World J. Gastroenterol., 2014, 20(30), 10425-10431.
[9]
Arnold, D.; Stein, A. New developments in the second-line treatment of metastatic colorectal cancer: Potential place in therapy. Drugs, 2013, 73(9), 883-891.
[10]
Cunningham, D.; Atkin, W.; Lenz, H-J.; Lynch, H.T.; Minsky, B.; Nordlinger, B.; Starling, N. Colorectal cancer. Lancet, 2010, 375(9719), 1030-1047.
[11]
Goldberg, R.M. Therapy for metastatic colorectal cancer. Oncologist, 2006, 11(9), 981-987.
[12]
Gustavsson, B.; Carlsson, G.; Machover, D.; Petrelli, N.; Roth, A.; Schmoll, H-J.; Tveit, K-M.; Gibson, F. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin. Colorectal Cancer, 2015, 14(1), 1-10.
[13]
Rougier, P.; Lepere, C. Second-line treatment of patients with metastatic colorectal cancer. Semin. Oncol., 2005, 32(6)(Suppl. 9), S48-S54.
[14]
Seiwert, T.Y.; Haraf, D.J.; Cohen, E.E.W.; Stenson, K.; Witt, M.E.; Dekker, A.; Kocherginsky, M.; Weichselbaum, R.R.; Chen, H.X.; Vokes, E.E. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol., 2008, 26(10), 1732-1741.
[15]
Okita, N.T.; Esaki, T.; Baba, E.; Sakai, D.; Tokunaga, S.; Takiuchi, H.; Mizunuma, N.; Nagashima, K.; Kato, K. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest. New Drugs, 2012, 30(5), 2026-2031.
[16]
Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
[17]
Saltz, L.B.; Clarke, S.; Díaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T-S.; Rivera, F.; Couture, F.; Sirzén, F.; Cassidy, J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J. Clin. Oncol., 2008, 26(12), 2013-2019.
[18]
Hess, G.P.; Wang, P.F.; Quach, D.; Barber, B.; Zhao, Z. Systemic therapy for metastatic colorectal cancer: Patterns of chemotherapy and biologic therapy use in US medical oncology practice. J. Oncol. Pract., 2010, 6(6), 301-307.
[19]
Giantonio, B.J.; Catalano, P.J.; Meropol, N.J.; O’Dwyer, P.J.; Mitchell, E.P.; Alberts, S.R.; Schwartz, M.A.; Benson, A.B. Eastern Cooperative Oncology Group Study, E. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 25(12), 1539-1544.
[20]
Roqué, I.; Figuls, M.; Solà, I.; Martin-Richard, M.; López, J-J.; Bonfill Cosp, X. Second-line chemotherapy in advanced and metastatic CRC. Cochrane Database Syst. Rev., 2009, CD006875.
[21]
Sørbye, H.; Berglund, A.; Tveit, K.M.; Ogreid, D.; Wanderås, E.H.; Wentzel-Larsen, T.; Dahl, O.; Glimelius, B. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol., 2007, 46(7), 982-988.
[22]
Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8, 16.
[23]
Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, 21(11), 1539-1558.
[24]
Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414), 557-560.
[25]
Hecht, J.R.; Cohn, A.; Dakhil, S.; Saleh, M.; Piperdi, B.; Cline-Burkhardt, M.; Tian, Y.; Go, W.Y. SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin. Colorectal Cancer, 2015, 14(2), 72-80.
[26]
Bennouna, J.; Sastre, J.; Arnold, D.; Österlund, P.; Greil, R.; Van Cutsem, E.; von Moos, R.; Viéitez, J.M.; Bouché, O.; Borg, C.; Steffens, C-C.; Alonso-Orduña, V.; Schlichting, C.; Reyes-Rivera, I.; Bendahmane, B.; André, T.; Kubicka, S.; Investigators, M.L.S. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol., 2013, 14(1), 29-37.
[27]
Cao, R.; Zhang, S.; Ma, D.; Hu, L. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med. Oncol., 2015, 32(1), 325.
[28]
Masi, G.; Salvatore, L.; Boni, L.; Loupakis, F.; Cremolini, C.; Fornaro, L.; Schirripa, M.; Cupini, S.; Barbara, C.; Safina, V.; Granetto, C.; Fea, E.; Antonuzzo, L.; Boni, C.; Allegrini, G.; Chiara, S.; Amoroso, D.; Bonetti, A.; Falcone, A.; Investigators, B.S. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial. Ann. Oncol., 2015, 26(4), 724-730.
[29]
Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; Williamson, S.K.; Findlay, B.P.; Pitot, H.C.; Alberts, S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol., 2004, 22(1), 23-30.
[30]
Cassidy, J.; Clarke, S.; Díaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T-S.; Rivera, F.; Couture, F.; Sirzén, F.; Saltz, L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(12), 2006-2012.
[31]
Falcone, A.; Ricci, S.; Brunetti, I.; Pfanner, E.; Allegrini, G.; Barbara, C.; Crinò, L.; Benedetti, G.; Evangelista, W.; Fanchini, L.; Cortesi, E.; Picone, V.; Vitello, S.; Chiara, S.; Granetto, C.; Porcile, G.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Masi, G.; Gruppo Oncologico Nord, O. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J. Clin. Oncol., 2007, 25(13), 1670-1676.
[32]
Welch, S.; Spithoff, K.; Rumble, R.B.; Maroun, J. Gastrointestinal Cancer Disease Site, G. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: A systematic review. Ann. Oncol., 2010, 21(6), 1152-1162.
[33]
Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J.T.; Aparicio, J.; de Braud, F.; Donea, S.; Ludwig, H.; Schuch, G.; Stroh, C.; Loos, A.H.; Zubel, A.; Koralewski, P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 2009, 27(5), 663-671.
[34]
Douillard, J-Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J-L.; Rother, M.; Oliner, K.S.; Wolf, M.; Gansert, J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J. Clin. Oncol., 2010, 28(31), 4697-4705.
[35]
Peeters, M.; Price, T.J.; Cervantes, A.; Sobrero, A.F.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.J.A.; Strickland, A.H.; Wilson, G.; Ciuleanu, T-E.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.S.; Rong, A.; Gansert, J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol., 2010, 28(31), 4706-4713.
[36]
Cohn, A.L.; Tabernero, J.; Maurel, J.; Nowara, E.; Sastre, J.; Chuah, B.Y.S.; Kopp, M.V.; Sakaeva, D.D.; Mitchell, E.P.; Dubey, S.; Suzuki, S.; Hei, Y.J.; Galimi, F.; McCaffery, I.; Pan, Y.; Loberg, R.; Cottrell, S.; Choo, S.P. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann. Oncol., 2013, 24(7), 1777-1785.
[37]
van Geelen, C.M.; Westra, J.L.; de Vries, E.G.; Boersma-van Ek, W.; Zwart, N.; Hollema, H.; Boezen, H.M.; Mulder, N.H.; Plukker, J.T.; de Jong, S.; Kleibeuker, J.H.; Koornstra, J.J. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J. Clin. Oncol., 2006, 24(31), 4998-5004.
[38]
Hakam, A.; Yeatman, T.J.; Lu, L.; Mora, L.; Marcet, G.; Nicosia, S.V.; Karl, R.C.; Coppola, D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol., 1999, 30(10), 1128-1133.
[39]
Ishigami, S.I.; Arii, S.; Furutani, M.; Niwano, M.; Harada, T.; Mizumoto, M.; Mori, A.; Onodera, H.; Imamura, M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer, 1998, 78(10), 1379-1384.
[40]
Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3(6), 401-410.
[41]
Loupakis, F.; Bria, E.; Vaccaro, V.; Cuppone, F.; Milella, M.; Carlini, P.; Cremolini, C.; Salvatore, L.; Falcone, A.; Muti, P.; Sperduti, I.; Giannarelli, D.; Cognetti, F. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials. J. Exp. Clin. Cancer Res., 2010, 29, 58.
[42]
Tebbutt, N.C.; Wilson, K.; Gebski, V.J.; Cummins, M.M.; Zannino, D.; van Hazel, G.A.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.P.; Forgeson, G.; Cunningham, D.; Saunders, M.P.; Stockler, M.R.; Chua, Y.; Zalcberg, J.R.; Simes, R.J.; Price, T.J. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol., 2010, 28(19), 3191-3198.
[43]
Mellor, H.R.; Callaghan, R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology, 2008, 81(4), 275-300.
[44]
Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8(8), 592-603.
[45]
Giantonio, B.J. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat. Rev. Clin. Oncol., 2009, 6(6), 311-312.
102
6
1